Tirosint-SOL

ApprovedSmall molecule

IIBSA Institut Biochimique SA

Tirosint-SOL is one of 4 small molecule programs targeting Congenital Hypothyroidism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital HypothyroidismActive, not recruiting

Congenital HypothyroidismApproved

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Congenital Hypothyroidism

#DrugCompanyPhaseTrials

Levothyroxine Sodium

Mylan Pharmaceuticals Inc

Approved

1 2

Levothyroxin

BBerlin-Chemie AG Menarini Group

Approved

1 3

Tirosint-SOL

IIBSA Institut Biochimique SA

Approved

1 4

Synthroid

IInstitut Jerome Lejeune

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congenital Hypothyroidism1 trial

A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism

Terminated·IIBSA Institut Biochimique SA·Approved·NCT05228184·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tirosint-SOL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tirosint-SOL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tirosint-SOL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IBSA Institut Biochimique SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IIBSA Institut Biochimique SA

Tirosint-SOL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congenital Hypothyroidism1 trial

References

Drug Info

Quick Facts

Related News